Author

Wanqin Zeng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations

Abstract Antibody–drug conjugates (ADCs) have become a major therapeutic class in breast cancer, but their clinical performance cannot be predicted by antigen expression alone. This review uses therapeutic-window engineering as a unifying framework to connect ADC molecular architecture with tumor heterogeneity, clinica...

Shi-Yan Zeng, Li Wang, Wan-Qin Zeng et al. · Drug Design, Development and... · 0 citations

Review Open access Jul 2026

Lactate-driven metabolic–epigenetic reprogramming in breast cancer: immune evasion and therapeutic resistance

Lactylation should be considered a candidate mechanism of durable state fixation rather than a universal explanation for lactate-associated effects, and future studies integrating direct lactylation measurements, spatial multi-omics, functional perturbation, and patient-derived models will be required to define clinica...

Lei Sun, Li Wang, Wan-Qin Zeng et al. · Clinical Epigenetics · 0 citations